Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) will present two preclinical posters at the AACR Annual Meeting in San Diego, April 17-22, 2026. Both presentations are scheduled on April 20, 2026 in the session "Experimental and Molecular Therapeutics: Cellular Responses to Anticancer Drugs."
Poster 2950 reports that palazestrant recruits corepressor NCoR1 leading to complete ERα antagonism; poster 2949 describes palazestrant plus OP-3136 synergistically downregulating proliferation and metastasis gene signatures.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
OLMA gained 12.85% while close biotech peers like ARVN, SAGE, ORKA, and VSTM showed declines and BCAX was roughly flat. Only one peer (TYRA) appeared in momentum scans, moving modestly higher, underscoring a stock‑specific reaction to OLMA’s AACR preclinical poster news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 16 | Earnings & pipeline | Positive | +9.6% | Q4/FY 2025 results, $218.5M raise, $505.4M cash and late-stage pipeline progress. |
| Mar 03 | Inducement grants | Neutral | +3.9% | Inducement stock options for four new employees under Nasdaq Listing Rule 5635(c)(4). |
| Feb 19 | Conference presentation | Neutral | +1.1% | Announcement of CEO presentation at TD Cowen 46th Annual Health Care Conference. |
| Feb 04 | Investor conferences | Neutral | -5.0% | Participation in three February 2026 investor conferences and related webcasts. |
| Feb 03 | Inducement grants | Neutral | +0.8% | Inducement options for two new employees totaling 24,000 shares under 2022 plan. |
Recent news across earnings, insider grants, and conferences has most often coincided with positive or modestly positive price moves, with only one notable decline on routine conference participation.
Over the last few months, OLMA has highlighted a strengthening balance sheet and advancing breast cancer pipeline. An earnings update on Mar 16, 2026 noted a follow-on raise of about $218.5M and year-end cash of $505.4M, and the stock rose 9.59%. Earlier, inducement option grants on Feb 3 and Mar 3 saw small gains. Investor conference announcements on Feb 4 triggered a -5.05% move, while a TD Cowen appearance on Feb 19 had a mild positive reaction. Today’s AACR preclinical posters extend this cadence of pipeline-visibility events.
Market Pulse Summary
This announcement highlights upcoming AACR 2026 preclinical posters for palazestrant and the KAT6 inhibitor OP‑3136, including combination data on cell proliferation and metastasis-related gene signatures. In recent filings, Olema has emphasized palazestrant’s pivotal Phase 3 program and initial OP‑3136 clinical data expected in Q2 2026. Investors may focus on how these mechanistic AACR findings complement existing clinical results and whether they support the company’s broader plans in ER‑positive breast cancer.
Key Terms
preclinical medical
metastasis medical
american association for cancer research medical
AI-generated analysis. Not financial advice.
SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present two preclinical posters at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22 in San Diego, California.
Poster Presentation Details
Title: Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alpha
Poster/Abstract: 2950
Session: Experimental and Molecular Therapeutics: Cellular Responses to Anticancer Drugs
Date/Time: April 20, 2026, from 2:00-5:00pm PT / 5:00pm-8:00pm ET
Title: Palazestrant, a CERAN, in combination with OP-3136, a KAT6 inhibitor, synergistically downregulates cell proliferation and metastasis related gene signatures
Poster/Abstract: 2949
Session: Experimental and Molecular Therapeutics: Cellular Responses to Anticancer Drugs
Date/Time: April 20, 2026, from 2:00pm-5:00pm PT / 5:00pm-8:00pm ET
Additional information can be found on the AACR Annual Meeting website.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
About Palazestrant (OP-1250)
Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In clinical studies, palazestrant completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer and has demonstrated anti-tumor efficacy along with attractive pharmacokinetics and exposure, favorable tolerability, central nervous system penetration, and combinability with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated as a single agent in the ongoing pivotal Phase 3 clinical trial, OPERA-01, and in combination with ribociclib in the ongoing pivotal Phase 3 clinical trial, OPERA-02. Palazestrant is also being evaluated in multiple Phase 1/2 studies in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib.
About OP-3136
OP-3136 is a novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target that is dysregulated in breast and other cancers. In preclinical studies, OP-3136 has demonstrated significant anti-proliferative activity in ER+ breast cancer models and is combinable and synergistic with endocrine therapies including palazestrant and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The Investigational New Drug (IND) application for OP-3136 was cleared by the U.S. Food and Drug Administration (FDA) in December 2024 and patients are currently enrolling in the Phase 1 clinical study.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “anticipate,” “believe,” “could,” “expect,” “goal,” “intend,” “may,” “on track,” “potential,” “upcoming,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the potential beneficial characteristics including but not limited to safety, tolerability, activity, efficacy and therapeutic effects of palazestrant or OP-3136, the combinability of palazestrant or OP-3136 with other drugs, including in the metastatic setting, and the timelines for enrollment for current clinical studies and for the receipt and presentation of results of clinical trials of palazestrant and OP-3136 each as a monotherapy and in combination trials. Because such statements deal with future events and are based on Olema’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, those discussed in the section titled “Risk Factors” in Olema’s Annual Report on Form 10-K for the year ended December 31, 2025, and future filings and reports that Olema makes from time to time with the U.S. Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements, including in the event that actual results differ materially from those anticipated in the forward-looking statements.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
When will Olema (OLMA) present at the AACR Annual Meeting in 2026?
What does Olema's poster 2950 say about palazestrant (OLMA)?
What is the focus of Olema's poster 2949 on palazestrant and OP-3136?
Where can investors find Olema (OLMA) AACR presentation details and timing?
